By otakuyassine3@gmail.com 
Duncan Williams Asset Management LLC boosted its position in Danaher Co. (NYSE:DHR – Free Report) by 7.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 4,477 shares of the conglomerate’s stock after acquiring an additional 301 shares during the period. Duncan Williams Asset Management LLC’s holdings in Danaher were worth $1,028,000 as of its most recent SEC filing.
Several other institutional investors have also added to or reduced their stakes in DHR. Fort Pitt Capital Group LLC lifted its position in shares of Danaher by 3.2% during the third quarter. Fort Pitt Capital Group LLC now owns 238,092 shares of the conglomerate’s stock worth $66,194,000 after acquiring an additional 7,421 shares in the last quarter. Good Life Advisors LLC purchased a new stake in shares of Danaher in the third quarter worth about $217,000. ORG Partners LLC boosted its position in shares of Danaher by 1,212.8% in the fourth quarter. ORG Partners LLC now owns 2,770 shares of the conglomerate’s stock valued at $636,000 after acquiring an additional 2,559 shares during the period. Harvest Portfolios Group Inc. grew its stake in Danaher by 1.2% during the third quarter. Harvest Portfolios Group Inc. now owns 202,263 shares of the conglomerate’s stock valued at $56,233,000 after acquiring an additional 2,465 shares in the last quarter. Finally, Stifel Financial Corp increased its holdings in Danaher by 1.3% during the 3rd quarter. Stifel Financial Corp now owns 847,348 shares of the conglomerate’s stock worth $235,583,000 after acquiring an additional 11,216 shares during the period. 79.05% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of research analysts have recently commented on DHR shares. Royal Bank of Canada reduced their price target on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. Stephens reiterated an “overweight” rating and set a $315.00 price target on shares of Danaher in a research report on Wednesday, October 23rd. KeyCorp upped their price objective on shares of Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 23rd. UBS Group dropped their target price on shares of Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a research report on Wednesday, October 23rd. Finally, TD Cowen increased their price target on shares of Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a report on Wednesday, October 23rd. Six research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to MarketBeat, Danaher presently has an average rating of “Moderate Buy” and a consensus target price of $285.55.
Read Our Latest Analysis on DHR
Danaher Stock Up 0.1 %
NYSE DHR opened at $245.95 on Friday. Danaher Co. has a 1 year low of $225.42 and a 1 year high of $281.70. The stock has a market capitalization of $177.65 billion, a PE ratio of 46.94, a PEG ratio of 4.43 and a beta of 0.83. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The business’s 50-day moving average is $235.33 and its 200 day moving average is $253.45.
Danaher Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be paid a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. Danaher’s dividend payout ratio (DPR) is presently 20.61%.
Danaher Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
See Also
Receive News & Ratings for Danaher Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Danaher and related companies with MarketBeat.com’s FREE daily email newsletter.